BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 1944423)

  • 21. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.
    Black S; France EK; Isaacman D; Bracken L; Lewis E; Hansen J; Fireman B; Austrian R; Graepel J; Gray S; Klein NP
    Pediatr Infect Dis J; 2007 Sep; 26(9):771-7. PubMed ID: 17721369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)].
    Artiles F; Horcajada I; Cañas AM; Alamo I; Bordes A; González A; Santana M; Lafarga B
    Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):14-21. PubMed ID: 19217998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.
    Vila-Corcoles A; Salsench E; Rodriguez-Blanco T; Ochoa-Gondar O; de Diego C; Valdivieso A; Hospital I; Gomez-Bertomeu F; Raga X
    Vaccine; 2009 Mar; 27(10):1504-10. PubMed ID: 19171174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
    Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
    N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pneumococcal vaccine.
    LaForce FM
    Semin Respir Infect; 1989 Dec; 4(4):293-8. PubMed ID: 2697052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly.
    Honkanen PO; Keistinen T; Kivelä SL
    Arch Intern Med; 1996 Jan; 156(2):205-8. PubMed ID: 8546555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
    Haber M; Barskey A; Baughman W; Barker L; Whitney CG; Shaw KM; Orenstein W; Stephens DS
    Vaccine; 2007 Jul; 25(29):5390-8. PubMed ID: 17583392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential.
    Hsieh YC; Lin PY; Chiu CH; Huang YC; Chang KY; Liao CH; Chiu NC; Chuang YC; Chen PY; Chang SC; Liu JW; Yen MY; Wang JH; Liu CY; Lin TY
    Vaccine; 2009 Sep; 27(40):5513-8. PubMed ID: 19615960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine.
    Muñoz-Almagro C; Jordan I; Gene A; Latorre C; Garcia-Garcia JJ; Pallares R
    Clin Infect Dis; 2008 Jan; 46(2):174-82. PubMed ID: 18171247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study.
    Whitney CG; Pilishvili T; Farley MM; Schaffner W; Craig AS; Lynfield R; Nyquist AC; Gershman KA; Vazquez M; Bennett NM; Reingold A; Thomas A; Glode MP; Zell ER; Jorgensen JH; Beall B; Schuchat A
    Lancet; 2006 Oct; 368(9546):1495-502. PubMed ID: 17071283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas.
    Techasaensiri C; Messina AF; Katz K; Ahmad N; Huang R; McCracken GH
    Pediatr Infect Dis J; 2010 Apr; 29(4):294-300. PubMed ID: 19949357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-sectional study of nasopharyngeal carriage of Streptococcus pneumoniae in human immunodeficiency virus-infected adults in the conjugate vaccine era.
    Onwubiko C; Swiatlo E; McDaniel LS
    J Clin Microbiol; 2008 Nov; 46(11):3621-5. PubMed ID: 18845823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bacteremic pneumococcal pneumonia].
    Pineda Solas V; Pérez Benito A; Domingo Puiggros M; Larramona Carrera H; Segura Porta F; Fontanals Aymerich D
    An Esp Pediatr; 2002 Nov; 57(5):408-13. PubMed ID: 12467543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations.
    Butler JC; Breiman RF; Campbell JF; Lipman HB; Broome CV; Facklam RR
    JAMA; 1993 Oct; 270(15):1826-31. PubMed ID: 8411526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adults with invasive pneumococcal disease: missed opportunities for vaccination.
    Kyaw MH; Greene CM; Schaffner W; Ray SM; Shapiro M; Barrett NL; Gershman K; Craig AS; Roberson A; Zell ER; Schuchat A; Bennett NM; Whitney CG;
    Am J Prev Med; 2006 Oct; 31(4):286-92. PubMed ID: 16979452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children.
    Kaplan SL; Barson WJ; Lin PL; Stovall SH; Bradley JS; Tan TQ; Hoffman JA; Givner LB; Mason EO
    Pediatrics; 2010 Mar; 125(3):429-36. PubMed ID: 20176669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study.
    Simberkoff MS; Cross AP; Al-Ibrahim M; Baltch AL; Geiseler PJ; Nadler J; Richmond AS; Smith RP; Schiffman G; Shepard DS
    N Engl J Med; 1986 Nov; 315(21):1318-27. PubMed ID: 3534568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asthma as a risk factor for invasive pneumococcal disease.
    Talbot TR; Hartert TV; Mitchel E; Halasa NB; Arbogast PG; Poehling KA; Schaffner W; Craig AS; Griffin MR
    N Engl J Med; 2005 May; 352(20):2082-90. PubMed ID: 15901861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy.
    Ammann AJ; Addiego J; Wara DW; Lubin B; Smith WB; Mentzer WC
    N Engl J Med; 1977 Oct; 297(17):897-900. PubMed ID: 20575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.